Cargando…
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
SIMPLE SUMMARY: Immune-oncology has revolutionized the natural history of many cancers in the past decade, becoming a new therapeutic weapon. The identification of immune “checkpoints” (PD-1/CTLA-4) whose blockade stimulates anti-tumor immunity has changed outcomes for many ptients. However, immune...
Autores principales: | Longhitano, Elisa, Muscolino, Paola, Lo Re, Claudia, Ferrara, Serena Ausilia, Cernaro, Valeria, Gembillo, Guido, Tessitore, Dalila, Speranza, Desirèe, Figura, Francesco, Santarpia, Mariacarmela, Silvestris, Nicola, Santoro, Domenico, Franchina, Tindara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046877/ https://www.ncbi.nlm.nih.gov/pubmed/36980777 http://dx.doi.org/10.3390/cancers15061891 |
Ejemplares similares
-
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
por: Spagnolo, Calogera Claudia, et al.
Publicado: (2022) -
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023) -
Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions
por: Cernaro, Valeria, et al.
Publicado: (2023) -
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022) -
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)